Oncoloxía médica
Servicio
National Taiwan University Hospital
Taipéi, TaiwánPublicacións en colaboración con investigadores/as de National Taiwan University Hospital (5)
2022
-
A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer
Clinical Cancer Research, Vol. 28, Núm. 1, pp. 106-115
2020
-
Brigatinib Versus Crizotinib in Advanced ALK Inhibitor–Naive ALK-Positive Non–Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial
Journal of Clinical Oncology
-
Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial
The Lancet Respiratory Medicine, Vol. 8, Núm. 11, pp. 1132-1143
2018
-
Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer
New England Journal of Medicine, Vol. 379, Núm. 21, pp. 2027-2039